Vinge advises Danish healthcare company Coloplast on its acquisition of Atos Medical, the global market leader in laryngectomy for EUR 2.155 billion (around DKK 16 billion) from PAI Partners, a global private equity firm headquartered in Paris. Closing of the transaction is subject to customary regulatory approvals and anticipated to occur in Q2 2021/22.

Vinge’s team primarily consisted of Matthias Pannier, Ulrich Ziche, Vilhelm Rondahl, Clara Sohlberg and Julia Hagelberg (M&A), Klara Secher and Axel Lennartsson (IP), Lisa Hörnqvist and Mario Saad (Agreements and IT), Karl-Hugo Engdahl and Karolina Fuhrman (GDPR), Tove Lövgren Frisk (Compliance), Jolinn Uhlin and Michaela Ådén (Banking & Financing), Elin Broman (Employment) and Lina Österberg and Ulf Pyk (Real Estate). Kromann Reumert acted as lead counsel for Coloplast.

Related

Vinge advises Aspo on its acquisition of Swed Handling

Vinge advises Aspo, listed on Nasdaq Helsinki, in the transaction whereby Aspo's subsidiary Telko expands its chemicals business in Sweden by acquiring Swed Handling, a leading Swedish chemical distributor, from TeRa Invest. As part of the transaction, Aspo’s subsidiary Leipurin expands its food industry business in Sweden, via the technical food ingredient distributor Kebelco, which is a subsidiary of Swed Handling. The closing of the transaction is subject to customary regulatory approvals.
April 30, 2024

Vinge advises on the sale of Vinnergi Holding AB

Vinge has advised Sobro and other shareholders in connection with the sale of Vinnergi Holding AB to Polaris, a Nordic investment firm. In connection with the transaction, the management and employees are reinvesting a significant portion to further develop the company. The Vinnergi Group conducts operations in technology consulting and software development in Sweden, with a particular focus on telecoms, energy and real estate.
April 30, 2024

Vinge has advised Pareto Securities in connection with a rights issue in Episurf Medical

Vinge has advised Pareto Securities in connection with a partially secured rights issue of units of up to approximately SEK 120 million in Episurf Medical.
April 24, 2024